Balance Labs Files 10-Q, Details Q2 Financials

TL;DR

Balance Labs 10-Q dropped: Q2 financials are in, check the balance sheet for key numbers.

AI Summary

Balance Labs, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details the company's financial position and performance, including balance sheet information as of June 30, 2024, and December 31, 2023. Specific financial statement data, such as common stock, additional paid-in capital, and retained earnings, are presented for various comparative periods.

Why It Matters

This 10-Q filing provides investors and analysts with a crucial update on Balance Labs, Inc.'s financial health and operational performance for the second quarter of 2024.

Risk Assessment

Risk Level: low — This filing is a standard quarterly report and does not contain immediate red flags or significant negative news.

Key Numbers

• N/A — Revenue (Specific revenue figures are not detailed in the provided header information.)
• N/A — Net Income (Specific net income figures are not detailed in the provided header information.)
• N/A — Total Assets (Specific total asset figures are not detailed in the provided header information.)

Key Players & Entities

• Balance Labs, Inc. (company) — Filer of the 10-Q
• June 30, 2024 (date) — End of reporting period
• December 31, 2023 (date) — Comparative balance sheet date

FAQ

Filing Documents

• form10-q.htm (10-Q) — 554KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 19KB
• ex32-1.htm (EX-32.1) — 9KB
• ex32-2.htm (EX-32.2) — 9KB
• 0001493152-24-031278.txt ( ) — 3257KB
• blnc-20240630.xsd (EX-101.SCH) — 21KB
• blnc-20240630_cal.xml (EX-101.CAL) — 29KB
• blnc-20240630_def.xml (EX-101.DEF) — 122KB
• blnc-20240630_lab.xml (EX-101.LAB) — 196KB
• blnc-20240630_pre.xml (EX-101.PRE) — 173KB
• form10-q_htm.xml (XML) — 432KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1. Financial Statements (unaudited) 4 Balance Sheets as of June 30, 2024 and December 31, 2023 (unaudited) 4 5 6 7 Condensed

Notes to Financial Statements (unaudited)

Notes to Financial Statements (unaudited) 8

Controls and Procedures

Item 4. Controls and Procedures. 23

- OTHER INFORMATION

PART II - OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings. 24

Risk Factors

Item 1A. Risk Factors. 24

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2 Unregistered Sales of Equity Securities and Use of Proceeds. 24

Defaults Upon Senior Securities

Item 3 Defaults Upon Senior Securities. 24

Mine Safety Disclosures

Item 4. Mine Safety Disclosures. 25

Other Information

Item 5. Other Information. 25

Exhibits

Item 6. Exhibits. 25

Signatures

Signatures 26 2 Explanatory Note: The registrant has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, however, the registrant is not subject to such fling requirements and is making such filings on a voluntary basis. 3 PART I - FINANCIAL INFORMATION Item 1. Financial Statements. Balance Labs, Inc. Consolidated Balance Sheets June 30, 2024 December 31, 2023 (Unaudited) Assets Current Assets Cash and cash equivalents $ 43,794 $ 112,809 Marketable securities 127,682 107,912 Total Current Assets 171,476 220,721 Total Assets $ 171,476 $ 220,721 Liabilities and Stockholders' Deficit Current Liabilities Accounts payable and accrued expenses $ 1,544,578 $ 1,381,849 Accounts payable - related party 911,659 911,659 Short -term advances - related party 1,673,558 1,673,558 Convertible note payable 25,000 25,000 Convertible notes payable - related party, net of debt discount of $ 0 and $ 0 , as of June 30, 2024 and December 31, 2023 173,192 173,192 Convertible note payable, net of debt discount of $ 2,835 and $ 8,504 , as of June 30, 2024 and December 31, 2023 497,165 491,496 Notes payable - related party - net of debt discount of $ 0 and $ 0 as of June 30, 2024 and December 31, 2023 106,850 106,850 Total Current Liabilities 4,932,002 4,763,604 Total Liabilities 4,932,002 4,763,604 Commitments and Contingencies (Note 8) - - Stockholders' Deficit Preferred stock, $ 0.0001 par value, 50,000,000 shares authorized, none issued and outstanding as of June 30, 2024 and December 31, 2023 - - Common stock, $ 0.0001 par value: authorized 500,000,000 , 21,674,000 and 21,674,000 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 2,167 2,167 Additional paid-in capital 810,048 810,048 Accumulated deficit ( 5,572,741 ) ( 5,355,098 ) Total Stockholders' Deficit ( 4,760,526

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements As of June 30, 2024 (Unaudited) Note 1 – Business Organization and Nature of Operations Balance Labs, Inc. ("Balance Labs" or the "Company") was incorporated on June 5, 2014, under the laws of the State of Delaware. Balance Labs is a consulting firm that provides business development and consulting services to start up and development stage businesses. The Company offers services to help businesses in various industries improve and fine tune their business models, sales and marketing plans and internal operations as well as make introductions to professional services such as business plan writing, accounting firms and legal service providers. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial position of Balance Labs as of June 30, 2024, and the unaudited consolidated results of its operations and cash flows for the three months ended June 30, 2024. The unaudited consolidated results of operations for the three months ended June 30, 2024, are not necessarily indicative of the operating results for the full year. It is recommended that these unaudited consolidated financial statements be read in conjunction with the audited financial statements and related disclosures of the Company for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission on April 15, 2024. Note 2 – Going Concern The consolidated financial statements have been prepared assuming the Company will con

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements As of June 30, 2024 (Unaudited) Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates may include those pertaining to stock-based compensation, depreciable lives of fixed assets and deferred tax assets. Actual results could materially differ from those estimates. Accounts Receivable The Company provides an allowance for doubtful accounts equal to the estimated uncollectible amounts pursuant to the guidance of Accounting Standards Update (ASU) 2016-13, Financial Instruments – Credit Losses (Topic 326) as codified in Accounts Standards Codification (ASC) 326, Financial Instruments – Credit Losses. Under ASC 326, the Company utilizes a current and expected credit loss (CECL) impairment model. ASU 2016-13 became effective for us on January 1, 2023. The Company's estimate is based on historical collection experience and a review of the current status of trade accounts receivable. It is reasonably possible that the Company's estimate of the allowance for doubtful accounts will change. Accounts receivable are presented net of an allowance for doubtful accounts of $ 0 and $ 0 at June 30, 2024 and December 31, 2023, respectively. Revenue Recognition The Company accounts for its revenues under FASB ASC 606, which is a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company considers revenue rea

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements As of June 30, 2024 (Unaudited) Management has evaluated and concluded that there are no material tax positions requiring recognition in the Company's unaudited condensed consolidated financial statements as of June 30, 2024. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company's, 2021, 2022, and 2023 tax returns remain open for audit for Federal and The Company's policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the statement of operations. Marketable Securities The Company accounts for marketable and available-for-sale securities under ASU 2016-01, "Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2016-01 requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The Company accounts for its investment in EZFill Holdings, Inc. as available-for-sale securities pursuant to the S-1 Registration Statement declared effective on September 14, 2021, therefore, the unrealized gain (loss) on the available-for-sale securities during the six months ended June 30, 2024, and 2023 has been recorded in Other Income. At June 30, 2024, the Company owned 66,432 shares and the fair value of the investment in EZFill Holdings, Inc. was reported on the balance sheet as Investment at fair value - related party totaling $ 127,682 ($ 1.92 /share). The Company recorded an adjustment of $ 19,770 for the six months ending June 30, 2024, as unrealized gain on securities. EZFill Holdings Inc. reported a 1 share for 8 share reverse stock split on April 26, 2023, which affected the total number of sha

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements As of June 30, 2024 (Unaudited) Investments – Related Parties When the fair value of an investment is indeterminable, the Company accounts for its investments that are under 20% of the total equity outstanding using the cost method. For investments in which the Company holds between 20-50% equity and is non-controlling are accounted for using the equity method. For any investments in which the Company holds over 50% of the outstanding stock, the Company consolidates those entities into their consolidated financial statements herein. The Company holds one investment as of June 30, 2024, and one investment as of December 31, 2023. Investments On January 29, 2021, the Company received 20 % ownership of Pharmacy No, 27, Ltd, a company based in Israel, as part of a Note Receivable from a third party. As of June 30, 2024, the investment has a fair value of $ 0 , based upon the quoted closing trading price and it is recorded on our consolidated balance sheet using the equity method. During each three months ended June 30, 2024 and December 31, 2023 the Company recorded $ 0 of unrealized loss from this investment. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and marketable securities. As of June 30, 2024, and December 31, 2023, the carrying value of marketable securities was $ 127,682 and $ 107,912 , respectively. The securities are included in the Investment at Fair Value – Related Party on the consolidated balance sheets, which consist of common shares held in one (1) investment which currently is trading on the Over-the-Counter Bulletin Board (OTCBB). Principles of Consolidation The consolidated financial statements include the Company and its wholly owned corporate subsidiaries, Balance Labs LLC. 11 BALANCE LABS, INC. Condensed

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements As of June 30, 2024 (Unaudited) Net Income (Loss) Per Common Share Basic and diluted income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares and warrants from convertible debentures outstanding during the periods. The effect 4,101,359 and 3,698,494 shares from convertible notes payable for the six months ended June 30, 2024, and 2023, respectively. Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Awards granted to directors are treated on the same basis as awards granted to employees. The Company has computed the fair value of warrants granted using the Black-Scholes option pricing model. The expected term used for warrants is the contractual life. Since the Company's stock has not been publicly traded for a sufficiently long period, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. Fair Value of Financial Instruments The Company measures its financial assets and liabilities in accordance with GAAP. For certain of our financial instruments, including cash,

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements As of June 30, 2024 (Unaudited) The following table presents certain assets of the Company's measured and recorded at fair value on the Company's balance sheet on a recurring basis and their level within the fair value hierarchy as of June 30, 2024. Schedule of Fair Value of Assets on Recurring Basis Total (Level 1) (Level 2) (Level 3) Fair-value – equity securities $ 127,682 $ 127,682 $ - $ - Total Assets measured at fair value $ 127,682 $ 127,682 $ - $ - The following table presents certain assets of the Company's measured and recorded at fair value on the Company's balance sheet on a recurring basis and their level within the fair value hierarchy as of December 31, 2023. Total (Level 1) (Level 2) (Level 3) Fair-value – equity securities $ 107,912 $ 107,912 $ - $ - Total Assets measured at fair value $ 107,912 $ 107,912 $ - $ - The Company accounts for its investment in EzFill Holdings, Inc. ("EzFill") as available-for-sale securities, since the investment is valued based on quoted market price using observable inputs.

Business

Business Segments The Company operates in one segment and therefore segment information is not presented. Advertising, Marketing and Promotional Costs Advertising, marketing, and promotional expenses are expensed as incurred and are included in selling, general and administrative expenses on the accompanying unaudited condensed consolidated statement of operations. For the six months ended June 30, 2024, and June 30, 2023, advertising, marketing, and promotion expense was $ 2,575 and $ 2,394 , respectively. Property and equipment Property and equipment consist of furniture and office equipment and is stated at cost less accumulated depreciation. Depreciation is determined by using the straight-line method for furniture and office equipment, over the estimated useful lives of the related assets, generally three to five years . Expenditures for repairs and maintenance of equipment are charged to expense as incurred. Major replacements and betterments are capitalized and depreciated over the remaining useful lives of the related assets. 13 BALANCE LABS, INC. Condensed

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements As of June 30, 2024 (Unaudited) Property and equipment as of June 30, 2024, and December 31, 2023 consisted of the following: Schedule of Property and Equipment June 30, 2024 December 31, 2023 (unaudited) Website $ 1,336 $ 1,336 Computer equipment & Software 5,358 5,358 Furniture 4,622 4,622 Total 11,316 11,316 Less Accumulated Depreciation ( 11,316 ) ( 11,316 ) Property and Equipment, net $ - $ - Recently Issued Accounting Pronouncements The Company has evaluated all new accounting standards that are in effect and may impact its unaudited condensed consolidated financial statements and does not believe that there are any other new accounting standards that have been issued that might have a material impact on its financial position or results of operations. Note 4 – Stockholders' Deficit Authorized Capital The Company is authorized to issue 500,000,000 shares of common stock, $ 0.0001 par value, and 50,000,000 shares of preferred stock, $ 0.0001 par value. 14 BALANCE LABS, INC. Condensed

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements As of June 30, 2024 (Unaudited) Note 5 – Note Receivable On September 30, 2021, Balance Labs Inc. made a loan to Four Acquisition, Ltd., an unrelated party in the principal amount of $ 22,000 which loan has an interest rate of 10 % per annum and a maturity date of September 30, 2022 . As of June 30, 2024, this receivable is fully reserved against. For the six months ended June 30, 2024 and 2023, the Company recorded $ 0 and $ 0 , respectively, of interest income in relation to this note. On January 29, 2021, Balance Labs Inc. made a loan to Four Acquisitions Ltd., an unrelated party in the principal amount of $ 119,000 which has an interest rate of 10 % per annum and a maturity date of January 28, 2022. Additionally, in connection with the loan, the Company received a 20 % interest in the recently acquired business and related assets of Four Acquisitions Ltd. Initially, this investment had a purchase price of $ 43,000 , which was recorded as a discount from the note which will be amortized over the life of the note. The Company recorded an allowance of 100 % against this receivable of $ 141,000 as of June 30, 2024. Note 6 – Related Party Transactions The Company's CEO earns $ 10,000 per month under a new agreement. This agreement is effective October 31, 2023. The following compensation was recorded within general and administrative expenses – related parties on the statements of operations: $ 30,000 and $ 30,000 for the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024 and December 31, 2023, $ 60,000 and $ 30,000 , respectively, of compensation was unpaid and was included in accounts payable – related party on the consolidated balance sheets. On April 1, 2016, the Company received $ 500,000 from Newell Trading Group in exchange for a convertible debenture due April 2, 2017 bearing interest at 10 % and convertible into common stock at $ .25 per share unless the note is paid by the C

View Full Filing

View this 10-Q filing on SEC EDGAR